Acorai, a health technology company based in Helsingborg, Sweden, has successfully raised $4.5 million to enhance its non-invasive cardiac care solutions. The funding comes from the European Innovation Council (EIC) Fund, Taiwan Medical University, and private investors. This capital will help Acorai complete its CAPTURE-HF clinical study, which has enrolled over 1,600 patients across 20 hospitals in six countries. The study aims to gather data for regulatory submissions in both the United States and Europe.
Acorai has already received FDA Breakthrough Device Designation and is participating in the FDA’s TAP Pilot program. The company plans to launch its product commercially by 2026. Additionally, the EIC Fund has provisioned another $6 million to support Acorai’s upcoming funding round in 2025, which will further validate its technology and facilitate early commercialization efforts. Acorai aims to transform cardiac care for more than 60 million heart failure patients worldwide.
The company’s flagship product, the SAVE Sensor System, utilizes advanced non-invasive technology to monitor cardiac health without invasive procedures. Acorai is currently involved in clinical trials to validate its approach and is focused on meeting regulatory standards while improving patient outcomes. By collaborating with healthcare institutions and strategic partners, Acorai seeks to address significant challenges in cardiac care with scalable and clinically validated solutions.
The CAPTURE-HF study has successfully completed patient enrollment, with over 1,600 participants involved. With the FDA’s Breakthrough Device Designation secured and ongoing collaboration with the FDA through the TAP Pilot program, Acorai is on track for regulatory submissions and aims for a commercial launch by 2026.
Related topics:
- Sweden’s Acorai Secures €4.2 Million to Enhance Heart Failure Management Devices, Plans Further Fundraising
- Emory Doctors Become First in the U.S. to Successfully Implant New Experimental Heart Pump
- Boehringer Ingelheim Launches FDA-Approved VETMEDIN Solution for Dogs with Congestive Heart Failure